BOSTON, Jan. 16, 2026 — Crosswalk Therapeutics, Inc., a biopharmaceutical company dedicated to creating new treatments for rare diseases with high unmet need, today announced the receipt of a National MPS Society research grant. This funding will advance early-stage development of a next-generation, enzyme-based therapy for Mucopolysaccharidosis IVA (MPS IVA), or Morquio A syndrome.

Morquio A syndrome is a rare genetic condition resulting from a deficiency in the GALNS enzyme, leading to progressive deterioration of skeletal and connective tissues. Although enzyme replacement therapy exists, its ability to affect bone and cartilage has been persistently limited, restricting its impact on the most debilitating disease aspects.

The grant will fund proof-of-concept studies for a novel fusion protein engineered to enhance enzyme function and its delivery to affected tissues. This initiative specifically targets the shortcomings of current enzyme treatments in reaching skeletal tissues, an area where existing therapies fall short.

“Morquio A syndrome is a devastating disorder with a major unmet need, especially concerning skeletal disease,” stated Madhu Natarajan, PhD, CEO of Crosswalk Therapeutics. “This grant allows us to explore a fundamentally new strategy for enzyme therapy, concentrating on optimizing enzyme design and tissue targeting. By utilizing modern computational methods, we aim to accelerate development while upholding a strong preclinical standard. We appreciate the National MPS Society’s support and our mutual dedication to research that prioritizes patients.”

“Our grant programs seek to fund promising research that tackles unmet needs in the MPS community,” said Scott Loiler, PhD, CSO of the National MPS Society. “This project demonstrates our dedication to progressing science that could shape future treatment options for those with Morquio A syndrome.”

While the primary target is MPS IVA, the core strategy is intended to guide future initiatives for other lysosomal storage disorders where limited tissue penetration reduces treatment efficacy.

About Crosswalk Therapeutics

Crosswalk Therapeutics is a biopharmaceutical company committed to developing innovative therapies for rare disorders with significant unmet medical needs. To learn more, visit  and follow us on .

SOURCE Crosswalk Therapeutics, Inc